Literature DB >> 1908891

Duration of etidronate effect demonstrated by serial bone scintigraphy.

E D Sandler1, M T Parisi, R S Hattner.   

Abstract

There have been several reports of etidronate disodium (EHDP) interference upon the biodistribution of 99mTc-methylene diphosphonate (MDP). With the increasing use of etidronate for the treatment of Paget's disease, hypercalcemia, and osteoporosis, nuclear physicians can expect to encounter increasing numbers of cases in which EHDP-induced artifacts impair the diagnostic utility of bone scans. The temporal duration of this effect is unknown yet obviously important. We report serial bone scintigraphy in a patient who received a single dose of EHDP for hypercalcemia. Normal biodistribution of 99mTc-MDP was noted at 15 days, suggesting that 2 wk are sufficient before performing a bone scan after a single intravenous dose of etidronate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1908891

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

Review 1.  Drug interactions with radiopharmaceuticals.

Authors:  S Hesslewood; E Leung
Journal:  Eur J Nucl Med       Date:  1994-04

2.  Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results.

Authors:  M P Roudier; H Vesselle; L D True; C S Higano; S M Ott; S H King; R L Vessella
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?

Authors:  Matthias Waldert; Tobias Klatte; Mesut Remzi; Helmut Sinzinger; Christian Kratzik
Journal:  World J Urol       Date:  2011-05-11       Impact factor: 4.226

Review 4.  Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  C J Dunn; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

5.  Altered Biodistribution of 99mTc-DPD on Bone Scan After Intravenous Iron Supplement.

Authors:  Eonwoo Shin; Minyoung Oh; Changhwan Sung; Ki-Hun Kim; Jin-Sook Ryu
Journal:  Nucl Med Mol Imaging       Date:  2017-07-25

6.  Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.

Authors:  Marnix G E H Lam; Amel Dahmane; Wil H M Stevens; Peter P van Rijk; John M H de Klerk; Bernard A Zonnenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-22       Impact factor: 9.236

7.  Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease.

Authors:  Nigora Rasulova; Vladimir Lyubshin; Dauranbek Arybzhanov; Sh Sagdullaev; Valery Krylov; Marat Khodjibekov
Journal:  World J Nucl Med       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.